Capital will fund Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through ...

Global Premiere Set for Rare Disease Day, Feb. 28, 2025ASHBURN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals ...

Pharmaceuticals has closed a royalty financing agreement with Castle Creek Biosciences to support the Phase 3 clinical study of ...

Quoin Pharmaceuticals (QNRX) announced the launch of the first episode in its “Living with Netherton” video series dedicated to giving voice to ...